Search Results
Apr 16, 2026, 09:00 ET New Open-Access Resource Hub Equips Educator Preparation Programs to Deliver Science of Reading Instruction
TeachSOR.org.**About Ibis Group**Ibis Group is a nonprofit that empowers students PK-16 with the knowledge and skills to become informed, engaged, and active participants in our democracy. Their strategy is to support systems that promote
More news about: Ibis Group and TeachSOR
Apr 15, 2026, 15:00 ET Perceptive Discovery Announces Strategic Partnership with MH3D and Launch of α-Sight™ to Advance Alpha Radiopharmaceutical Imaging
Xiaopei Huang, CEO and Founder at MH3D.α-Sight™ supports a range of applications, including biodistribution studies, tumor targeting validation, and PK/PD assessment, helping accelerate candidate selection and de-risk radioligand therapy development programs.About Perceptive DiscoveryPerceptive
More news about: Perceptive Discovery
Apr 15, 2026, 10:00 ET BlackArch Advises on the Sale of Pro-Surve to PK Companies
www.pro-surve.comAbout PK CompaniesPK Companies consist of PK Industrial, PK Technology & Inspection and PK Safety. Founded almost 30 years ago, PK is one of the only companies in existence today that can inspect, execute soft
More news about: BlackArch Partners
Apr 10, 2026, 08:30 ET MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs leading to treatment discontinuation. Secondary and exploratory endpoints include PK profiling and evaluation
More news about: MetaVia Inc.
Apr 09, 2026, 21:00 ET ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406
phase I trial is a single-center, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of AK0406 in healthy adult participants in Australia. Data from this FIH study will inform subsequent dose selection and future proof-of-concept
More news about: Arkbio
Apr 09, 2026, 21:00 ET ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406
phase I trial is a single-center, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of AK0406 in healthy adult participants in Australia. Data from this FIH study will inform subsequent dose selection and future proof-of-concept
More news about: Arkbio
Apr 09, 2026, 07:45 ET Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
Phase 1, Open-Label, Fixed-Sequence, Bidirectional,Pharmacokinetic (PK) Drug-DrugInteraction (DDI) Study BetweenCannabidiol (CBD) andCenobamate (CNB) in HealthyAdult Participants
More news about: Jazz Pharmaceuticals plc
Apr 08, 2026, 08:00 ET A-Street Secures New Capital from the LEGO Foundation and Members of the Walton Family to Scale PK-12 Learning Investments
to address the growing disconnect between the scale of innovation in PK-12 education and the outcomes students experience in classrooms and at home. A-Street has built a portfolio of companies tackling critical challenges across PK–12 education, including student engagement, instructional quality, and
More news about: A-Street
Apr 07, 2026, 09:00 ET Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China
U.S. Food and Drug Administration (FDA). The ongoing first-in-human Phase I study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of DXP-106 in patients with advanced solid tumors."Dosing of the first patient in
More news about: Singlomics Biopharmaceuticals
Apr 07, 2026, 08:40 ET NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer's Disease
analysis of the exploratory endpoints, the study met its core Phase 2a objectives and produced a positive multi-domain signal package across safety, PK, biomarkers, MRI, EEG, and clinical outcomes. This supports confidence in the further development of this new approach to treating Alzheimer's Disease."The
More news about: NeuroTherapia, Inc.
Apr 01, 2026, 12:41 ET PK Companies Acquires Pro-Surve Technical Services, Expanding National Inspection Capabilities and Technology Integration
solutions supported by the combined capabilities of both organizations. About PK CompaniesPK Companies consist of PK Industrial, PK Technology & Inspection, and PK Safety. Founded almost 30 years ago, PK is one of the only companies in existence today that can inspect, execute soft craft
More news about: PK Companies
Apr 01, 2026, 09:00 ET Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
least 12 weeks after multiple doses.Pharmacokinetics (PK): BBT001 exhibited prolonged PK with a half-life of approximately 33 days at or above target exposure after multiple doses, consistent with the PK observed in the SAD cohorts.Safety and Tolerability: BBT001
More news about: Bambusa Therapeutics, Inc.
Apr 01, 2026, 08:14 ET Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
interfering with life-saving cancer treatments.HT-001 was also well tolerated, with no treatment discontinuations reported.Pharmacokinetic (PK) analysis further demonstrated that HT-001 achieves approximately 99% lower systemic exposure compared to FDA-approved oral therapies, supporting a targeted
More news about: Hoth Therapeutics, Inc.
Apr 01, 2026, 08:00 ET New Documentary Explores How Young People Can Turn Civic Engagement into a Calling
roadtripnation.com.About Ibis GroupIbis Group is a nonprofit organization dedicated to building the knowledge and expanding the skills of PK-16 students to become literate, engaged, and contributing members of their communities. Their approach focuses on investing in dynamic leaders and organizations
More news about: Roadtrip Nation
Mar 31, 2026, 11:45 ET PK1Cloud a division of Perr&Knight and Pythia Announce Strategic Partnership to Deliver AI-Powered Intelligence to the P&C Insurance Market
systems and high-quality data environments. PK1Cloud provides that foundation by bringing together Perr&Knight's regulatory, actuarial, and product expertise within a secure, cloud-based platform designed for the insurance product lifecycle. By combining PK1Cloud's structured workflows and governance with
More news about: Perr&Knight
Mar 31, 2026, 11:30 ET Great Hearts Names Founding Headmaster at New Blossom Rock School
enrollaz.greatheartsamerica.org/meet-the-headmasterAbout Great HeartsGreat Hearts is a nonprofit and the nation's largest provider of classical PK–12 education, serving more than 30,000 students across 50 brick‑and‑mortar academies in Arizona, Texas, and Louisiana, along with a national online academy.
More news about: Great Hearts Arizona
Mar 31, 2026, 07:02 ET IIM Udaipur Confers Degrees on 481 Graduates at its 14th Convocation Ceremony
academic achievements of the students from the graduating batch.Ayushi Shukla, Divya Manchanda, Patil Nilesh Suresh, Nitin Jain, and Siddharth PK were conferred with the Doctor of Philosophy (PhD) degree, marking a significant academic milestone.Among the MBA programs, few students were
More news about: Indian Institute of Management Udaipur (IIMU)
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
applications guiding antibody sequence discovery, enrichment, optimization, bispecific geometry design, and developability/immunogenicity/pharmacokinetics (PK) assessments, as well as patient biomarker studies.CNS Disease Programs: Resilience Neuroscience, a wholly-owned subsidiary of the Company,
More news about: Harbour BioMed
Mar 30, 2026, 08:00 ET KBRO Leverages Harmonic's Fiber-on-Demand Solution for Network Upgrades
"We see the future of the broadband market in Taiwan to be defined by fiber-deep innovation and scalable infrastructure," said PK Lee, Vice President of Engineer at KBRO. "Our focus is on providing outstanding broadband experiences to our customers while managing our investments
More news about: Harmonic Inc.
Mar 27, 2026, 10:44 ET Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
WINLEVI cream.Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur during or after treatment with WINLEVI. In the pharmacokinetics (PK) trial, HPA axis suppression was observed in 1/20 (5%) of adult subjects and 2/22 (9%) of adolescent subjects at Day 14. All subjects returned to normal
More news about: Sun Pharma
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
February 2026. This multi-cohort, parallel expansion study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK)/Pharmacodynamics (PD) of CS2009 as monotherapy and in combination regimens in 15 cohorts across 9 solid tumor indications, including NSCLC, colorectal cancer
More news about: CStone Pharmaceuticals
Mar 26, 2026, 08:31 ET MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
two poster presentations at ObesityWeek® 2025. The Phase 1 data demonstrated favorable safety and tolerability, a newly characterized pharmacokinetic (PK) profile supporting once-weekly dosing, and meaningful reductions in body weight and waist circumference following four weeks of treatment. Additionally,
More news about: MetaVia Inc.
Mar 26, 2026, 07:00 ET BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
progressive GBM and other high-grade glioma. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.The Phase 2a expansion part of the trial is planned
More news about: BioLineRx Ltd.
Mar 25, 2026, 08:30 ET Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
seconds, which is expected to provide sufficient extracorporeal anticoagulation while minimally affecting systemic ACT. In conclusion, nafamostat has unique PK and PD properties, making it a suitable candidate for further evaluation as a regional anticoagulant in CRRT."While we are currently enrolling
More news about: Talphera, Inc.
Mar 25, 2026, 08:00 ET Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General Obesity
Endocrinology review outlines key characteristics necessary for next-generation MC treatments including high potency and preferred selectivity and PK profiles."Our analysis in Frontiers in Endocrinology shows that prior melanocortin system obesity drug development targeted MC4R selectively,
More news about: Kalohexis